Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
0% from low
Exchange
OTC Link
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $1.2M | $1.8M | $4.8M | $15.0M | $16.3M | $2.0M | $2.2M |
| Cost of revenue | $1.9M | $1.8M | $2.1M | $3.3M | $7.4M | $6.7M | $1.8M | $1.7M |
| Gross profit | −$86.4K | −$608.5K | −$299.3K | $1.5M | $7.7M | $9.6M | $178.0K | $496.0K |
| Gross margin | -4.7% | -49.5% | -16.6% | 31.7% | 51.0% | 59.2% | 8.8% | 22.4% |
| R&D | $522.8K | $233.8K | $63.2K | $0 | $715.1K | $859.0K | $121.0K | $2.1K |
| Operating income | −$13.8M | −$4.9M | −$20.1M | −$25.4M | −$28.3M | −$31.2M | −$4.8M | −$5.3M |
| EBITDA | −$13.2M | −$4.2M | −$21.3M | −$24.4M | −$24.6M | −$27.4M | −$3.9M | −$3.4M |
| Net income | −$13.9M | −$4.9M | −$22.0M | −$25.4M | −$26.0M | −$28.2M | −$25.7M | −$8.4M |
| Net margin | -756.1% | -399.2% | -1222.5% | -531.6% | -173.0% | -173.3% | -1273.3% | -379.8% |
| EPS (diluted) | -175.55 | -54.60 | -188.40 | -104.36 | -67.80 | -60.60 | -35.94 | -10.26 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $20M | $-18.15 | $-18.15–$-18.15 | 1 |
| 2027 | $2M | $30.84 | $30.84–$30.84 | 1 |
| 2028 | $2M | $-0.54 | $-0.54–$-0.54 | 1 |
| 2029 | $2M | $-0.54 | $-0.54–$-0.54 | 1 |
Forward consensus · source: Financial Modeling Prep
ADYNXX INC
No one on the platform currently holds ADYX.
No tracked institution reports a position in ADYX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2017-10-06 | 1-for-10reverse |
No one on the platform has traded ADYX yet.
| $107 |
| — |
| EFTReFFECTOR Therapeutics, Inc. | $0.00 | +0.00% | $2823 | — |
| FSPMFusionPharm, Inc. | $0.00 | +0.00% | $1259 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$ADYX Trying to finally sell my shares of this but there is no bid to even sell. Have to file a worthless stock form
View on StockTwits ↗$ADYX Over 4K watchers, anyone with a position here has an average over $1 and the stock is 0.001. Brutal
View on StockTwits ↗$NXGL $ADYX Parent company and subsidiary need to get their acts together… the share price hasn’t done 💩 all year long
View on StockTwits ↗$ADYX BUY/SELL METER Alert Cross 18% +- Technical Analysis https://t8sk.com/ADYX
View on StockTwits ↗$ADYX $NXGL Parent company of NexGel… I suspect whatever weird stuff is going on there is preventing NXGL from really taking off 🤔
View on StockTwits ↗$ADYX BUY/SELL METER Alert Cross 18% + 🚀 https://t8sk.com/ADYX
View on StockTwits ↗$ADYX this needs a good pump… just saying, you need an OTC play that can spike to $10 from under $1… this is it.. 👀 spread on the bid ask is unreal…
View on StockTwits ↗$ADYX - The variance is down to 208886.0... may suggest possible volatility slide https://www.macroaxis.com/invest/technicalIndicator/ADYX/Variance
View on StockTwits ↗$ADYX BUY/SELL METER Signal Cross 18% + 🚀 https://t8sk.com/ADYX
View on StockTwits ↗$ADYX BUY/SELL METER Signal Cross 18% + 🚀 https://t8sk.com/ADYX
View on StockTwits ↗$ADYX The Founder/CSO, Julien Mamet and the CEO/CFO, Rick Orr of Adynxx are actually working at a company called Exalys Therapeutics full time. No wonder ADYX hasn’t done anything for ages 😑
View on StockTwits ↗$ADYX shareholders down 99.99% here with the 0.01 bid
View on StockTwits ↗$NXGL $ADYX child and parent company.. red flags all around 🚩 🚩🚩🚩🚩🚩
View on StockTwits ↗$ADYX BUY/SELL METER Signal Cross 18% + 🚀 https://t8sk.com/ADYX
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.